Phase I Orally administered 14C-AZD2171 in patients with solid metastatic tumors
Study identifier:D8480C00019
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase 1, Open Label, Non-randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients with Solid Metastatic Tumours
Medical condition
advanced solid metastatic tumor
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171
Sex
All
Actual Enrollment
6
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2005
Primary Completion Date: -
Study Completion Date: 01 May 2006
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Nick Botwood
AstraZeneca
